Targeted Therapy for Hepatocellular Carcinoma

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Hepatocellular cancer (HCC) is a leading cause of cancer death worldwide, and most patients who are diagnosed with HCC are ineligible for curative local therapy. The targeted agent sorafenib provides modest survival benefits in the setting of advanced disease. Novel systemic treatment options for HCC are sorely needed. In this review, we identify and categorize the drugs and targets that are in various phases of testing for use against HCC. We also focus on the potential for combining these agents with radiotherapy. This would help identify directions for future study that are likely to yield positive findings and improve outcomes for patients with HCC.

Original languageEnglish (US)
Pages (from-to)338-343
Number of pages6
JournalSeminars in Radiation Oncology
Volume26
Issue number4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Therapeutics
Cause of Death
Radiotherapy
Survival
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Targeted Therapy for Hepatocellular Carcinoma. / Ohri, Nitin; Kaubisch, Andreas; Garg, Madhur K.; Guha, Chandan.

In: Seminars in Radiation Oncology, Vol. 26, No. 4, 01.10.2016, p. 338-343.

Research output: Contribution to journalReview article

@article{06cd0c13c59747fab2b04b785c7d6dc5,
title = "Targeted Therapy for Hepatocellular Carcinoma",
abstract = "Hepatocellular cancer (HCC) is a leading cause of cancer death worldwide, and most patients who are diagnosed with HCC are ineligible for curative local therapy. The targeted agent sorafenib provides modest survival benefits in the setting of advanced disease. Novel systemic treatment options for HCC are sorely needed. In this review, we identify and categorize the drugs and targets that are in various phases of testing for use against HCC. We also focus on the potential for combining these agents with radiotherapy. This would help identify directions for future study that are likely to yield positive findings and improve outcomes for patients with HCC.",
author = "Nitin Ohri and Andreas Kaubisch and Garg, {Madhur K.} and Chandan Guha",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.semradonc.2016.06.004",
language = "English (US)",
volume = "26",
pages = "338--343",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Targeted Therapy for Hepatocellular Carcinoma

AU - Ohri, Nitin

AU - Kaubisch, Andreas

AU - Garg, Madhur K.

AU - Guha, Chandan

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Hepatocellular cancer (HCC) is a leading cause of cancer death worldwide, and most patients who are diagnosed with HCC are ineligible for curative local therapy. The targeted agent sorafenib provides modest survival benefits in the setting of advanced disease. Novel systemic treatment options for HCC are sorely needed. In this review, we identify and categorize the drugs and targets that are in various phases of testing for use against HCC. We also focus on the potential for combining these agents with radiotherapy. This would help identify directions for future study that are likely to yield positive findings and improve outcomes for patients with HCC.

AB - Hepatocellular cancer (HCC) is a leading cause of cancer death worldwide, and most patients who are diagnosed with HCC are ineligible for curative local therapy. The targeted agent sorafenib provides modest survival benefits in the setting of advanced disease. Novel systemic treatment options for HCC are sorely needed. In this review, we identify and categorize the drugs and targets that are in various phases of testing for use against HCC. We also focus on the potential for combining these agents with radiotherapy. This would help identify directions for future study that are likely to yield positive findings and improve outcomes for patients with HCC.

UR - http://www.scopus.com/inward/record.url?scp=84995451844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995451844&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2016.06.004

DO - 10.1016/j.semradonc.2016.06.004

M3 - Review article

VL - 26

SP - 338

EP - 343

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 4

ER -